Literature DB >> 35833684

Decay of coronavirus disease 2019 mRNA vaccine-induced immunity in people with HIV.

Bezawit A Woldemeskel1, Andrew H Karaba1, Caroline C Garliss1, Evan J Beck2, Tihitina Y Aytenfisu1, Trevor S Johnston1, Oliver Laeyendecker2, Andrea L Cox1, Joel N Blankson1.   

Abstract

Current coronavirus disease 2019 (COVID-19) mRNA vaccines induce robust SARS-CoV-2-specific humoral and cellular responses in people with HIV (PWH). However, the rate of decay of effector immune responses has not been studied in these individuals. Here, we report a significant waning of antibody responses but persistent T-cell responses 6 months post vaccination in virally suppressed PWH with high CD4+ T-cell counts. These responses are comparable with those seen in healthy donors.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35833684      PMCID： PMC9473660          DOI： 10.1097/QAD.0000000000003263

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.632


  15 in total

1.  mRNA Vaccine-Elicited Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific T Cells Persist at 6 Months and Recognize the Delta Variant.

Authors:  Bezawit A Woldemeskel; Caroline C Garliss; Joel N Blankson
Journal:  Clin Infect Dis       Date:  2022-08-24       Impact factor: 20.999

2.  mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern.

Authors:  Rishi R Goel; Mark M Painter; Sokratis A Apostolidis; Divij Mathew; Wenzhao Meng; Aaron M Rosenfeld; Kendall A Lundgreen; Arnold Reynaldi; David S Khoury; Ajinkya Pattekar; Sigrid Gouma; Leticia Kuri-Cervantes; Philip Hicks; Sarah Dysinger; Amanda Hicks; Harsh Sharma; Sarah Herring; Scott Korte; Amy E Baxter; Derek A Oldridge; Josephine R Giles; Madison E Weirick; Christopher M McAllister; Moses Awofolaju; Nicole Tanenbaum; Elizabeth M Drapeau; Jeanette Dougherty; Sherea Long; Kurt D'Andrea; Jacob T Hamilton; Maura McLaughlin; Justine C Williams; Sharon Adamski; Oliva Kuthuru; Ian Frank; Michael R Betts; Laura A Vella; Alba Grifoni; Daniela Weiskopf; Alessandro Sette; Scott E Hensley; Miles P Davenport; Paul Bates; Eline T Luning Prak; Allison R Greenplate; E John Wherry
Journal:  Science       Date:  2021-12-03       Impact factor: 63.714

3.  Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial.

Authors:  Shabir A Madhi; Anthonet L Koen; Alane Izu; Lee Fairlie; Clare L Cutland; Vicky Baillie; Sherman D Padayachee; Keertan Dheda; Shaun L Barnabas; Qasim Ebrahim Bhorat; Carmen Briner; Parvinder K Aley; Sutika Bhikha; Tandile Hermanus; Elizea Horne; Aylin Jose; Prudence Kgagudi; Teresa Lambe; Masebole Masenya; Mduduzi Masilela; Nonhlanhla Mkhize; Andrew Moultrie; Christian K Mukendi; Thandeka Moyo-Gwete; Amit J Nana; Ayanda Nzimande; Faeezah Patel; Sarah Rhead; Carol Taoushanis; Asha Thombrayil; Samuel van Eck; Merryn Voysey; Tonya L Villafana; Johan Vekemans; Sarah C Gilbert; Andrew J Pollard; Penny L Moore; Gaurav Kwatra
Journal:  Lancet HIV       Date:  2021-08-17       Impact factor: 12.767

4.  HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform.

Authors:  Krishnan Bhaskaran; Christopher T Rentsch; Brian MacKenna; Anna Schultze; Amir Mehrkar; Chris J Bates; Rosalind M Eggo; Caroline E Morton; Sebastian C J Bacon; Peter Inglesby; Ian J Douglas; Alex J Walker; Helen I McDonald; Jonathan Cockburn; Elizabeth J Williamson; David Evans; Harriet J Forbes; Helen J Curtis; William J Hulme; John Parry; Frank Hester; Sam Harper; Stephen J W Evans; Liam Smeeth; Ben Goldacre
Journal:  Lancet HIV       Date:  2020-12-11       Impact factor: 12.767

5.  Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1.

Authors:  Itzchak Levy; Anat Wieder-Finesod; Vladyslav Litchevsky; Asaf Biber; Victoria Indenbaum; Liraz Olmer; Amit Huppert; Orna Mor; May Goldstein; Einav Gal Levin; Tammy Hod; Carmit Cohen; Yaniv Lustig; Galia Rahav
Journal:  Clin Microbiol Infect       Date:  2021-08-24       Impact factor: 8.067

6.  BNT162b2 mRNA COVID-19 vaccination in immunocompromised patients: A prospective cohort study.

Authors:  Galia Rahav; Yaniv Lustig; Jacob Lavee; Hila Magen; Tammy Hod; Einat Shacham Shmueli; Ziv Ben-Ari; Rebecca Halperin; Victoria Indenbaum; Liraz Olmer; Amit Huppert; Eytan Mor; Gili Regev-Yochay; Carmit Cohen; Anat Wieder- Finesod; Itzchak Levy
Journal:  EClinicalMedicine       Date:  2021-10-17

7.  Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months.

Authors:  Einav G Levin; Yaniv Lustig; Carmit Cohen; Ronen Fluss; Victoria Indenbaum; Sharon Amit; Ram Doolman; Keren Asraf; Ella Mendelson; Arnona Ziv; Carmit Rubin; Laurence Freedman; Yitshak Kreiss; Gili Regev-Yochay
Journal:  N Engl J Med       Date:  2021-10-06       Impact factor: 91.245

8.  Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV.

Authors:  Ane Ogbe; Matthew Pace; Mustapha Bittaye; Timothy Tipoe; Sandra Adele; Jasmini Alagaratnam; Parvinder K Aley; M Azim Ansari; Anna Bara; Samantha Broadhead; Anthony Brown; Helen Brown; Federica Cappuccini; Paola Cinardo; Wanwisa Dejnirattisai; Katie J Ewer; Henry Fok; Pedro M Folegatti; Jamie Fowler; Leila Godfrey; Anna L Goodman; Bethany Jackson; Daniel Jenkin; Mathew Jones; Stephanie Longet; Rebecca A Makinson; Natalie G Marchevsky; Moncy Mathew; Andrea Mazzella; Yama F Mujadidi; Lucia Parolini; Claire Petersen; Emma Plested; Katrina M Pollock; Thurkka Rajeswaran; Maheshi N Ramasamy; Sarah Rhead; Hannah Robinson; Nicola Robinson; Helen Sanders; Sonia Serrano; Tom Tipton; Anele Waters; Panagiota Zacharopoulou; Eleanor Barnes; Susanna Dunachie; Philip Goulder; Paul Klenerman; Gavin R Screaton; Alan Winston; Adrian Vs Hill; Sarah C Gilbert; Miles Carroll; Andrew J Pollard; Sarah Fidler; Julie Fox; Teresa Lambe; John Frater
Journal:  JCI Insight       Date:  2022-04-08

9.  Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial.

Authors:  John Frater; Katie J Ewer; Ane Ogbe; Mathew Pace; Sandra Adele; Emily Adland; Jasmini Alagaratnam; Parvinder K Aley; Mohammad Ali; M Azim Ansari; Anna Bara; Mustapha Bittaye; Samantha Broadhead; Anthony Brown; Helen Brown; Federica Cappuccini; Enya Cooney; Wanwisa Dejnirattisai; Christina Dold; Cassandra Fairhead; Henry Fok; Pedro M Folegatti; Jamie Fowler; Charlotte Gibbs; Anna L Goodman; Daniel Jenkin; Mathew Jones; Rebecca Makinson; Natalie G Marchevsky; Yama F Mujadidi; Hanna Nguyen; Lucia Parolini; Claire Petersen; Emma Plested; Katrina M Pollock; Maheshi N Ramasamy; Sarah Rhead; Hannah Robinson; Nicola Robinson; Patpong Rongkard; Fiona Ryan; Sonia Serrano; Timothy Tipoe; Merryn Voysey; Anele Waters; Panagiota Zacharopoulou; Eleanor Barnes; Susanna Dunachie; Philip Goulder; Paul Klenerman; Gavin R Screaton; Alan Winston; Adrian V S Hill; Sarah C Gilbert; Andrew J Pollard; Sarah Fidler; Julie Fox; Teresa Lambe
Journal:  Lancet HIV       Date:  2021-06-18       Impact factor: 12.767
View more
  1 in total

1.  Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Delta Variant Shedding in a Patient With AIDS: Case Report and Review of the Literature.

Authors:  Jillian L Peters; Amary Fall; Steven D Langerman; Margueritta El Asmar; Mari Nakazawa; Aishat Mustapha; Aaron A R Tobian; Heba H Mostafa; Joel N Blankson
Journal:  Open Forum Infect Dis       Date:  2022-09-17       Impact factor: 4.423
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.